#ophthalmology #optics #eyehealth #Santen #Ryjunea #paediatricmyopia #childhoodmyopia #marketingauthorisation #atropineeyedrop #childhoodeyecare #managingmyopia #children #myopiaprogression #SydnexisInc #phase3starstudy #shortsightedness #severeeyeconditions
pharmatimes.com/news/europea...
pharmatimes.com/news/europea...
EC approves Santen’s Ryjunea to slow progression of paediatric myopia - PharmaTimes
Therapy indicated for children aged 3 to 14 at treatment initiation
pharmatimes.com
June 5, 2025 at 10:12 AM